Medicines Company rises on 3Q sales gains, pipeline promise
This article was originally published in Scrip
Executive Summary
The Medicines Company's 27% increase in third quarter net revenue to $174.3m from $136.8m for the same period in 2012 was in line with market consensus of $173.3m, but net income of $0.12 per share versus $0.17 a year ago was below consensus expectations of $0.21.